<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A proliferation-inducing ligand (APRIL) is overexpressed in most <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and tissues, especially in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of the alimentary system, such as <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, and <z:hpo ids='HP_0002896'>liver cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi> interference (RNAi) has been proved to be a powerful tool for gene knockdown and holds great promise for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, the efficacy of RNAi targeting APRIL was analyzed via relevant experiments on human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> xenografted in BALB/c <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="3" pm="."><plain>Both the <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels of APRIL were examined after intratumoral injection of APRIL small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> (siRNA) </plain></SENT>
<SENT sid="4" pm="."><plain>Meanwhile, pathological tools were utilized to observe the alterations on the aspects of proliferation, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0000316'>cellular necrosis</z:mp> by means of detecting proliferating cell nuclear antigen, Ki-67, MMP-2, MMP-9, TIMP-3, TIMP-4, Bcl-2, Bax and Bcl-xL of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, terminal deoxyribonucleotidyl transferase-mediated <z:chebi fb="0" ids="17625">dUTP</z:chebi>-<z:chebi fb="0" ids="42098">digoxigenin</z:chebi> nick end-labeling (TUNEL) and <z:chebi fb="1" ids="51686">hematoxylin</z:chebi> and eosin staining were also conducted to examine cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0001651'>necrosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>It was found that grafted human <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e> growth and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> were obviously inhibited while <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:mp ids='MP_0001651'>necrosis</z:mp> were induced after in vivo APRIL siRNA injection into <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="7" pm="."><plain>The data indicated that silencing of the APRIL gene using RNAi may serve as a novel therapeutic strategy for treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>